We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Neoleukin Therapeutics Inc operates as a biopharmaceutical company. The firm generates immunotherapies using de novo protein design technology. It uses computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit o... Neoleukin Therapeutics Inc operates as a biopharmaceutical company. The firm generates immunotherapies using de novo protein design technology. It uses computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its product line comprises NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. Show more
0001404644FALSE00014046442024-03-182024-03-18UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORM 8-K CURRENT REPORTPursuant to Section 13 OR 15(d) of The Securities Exchange...
00014046442023FYFALSE0.25oneP6M00014046442023-01-012023-12-3100014046442023-06-30iso4217:USD00014046442024-03-13xbrli:shares00014046442022-01-012022-12-3100014046442023-12-3100014046442022-12-31000...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
="/Images/box-checked.jpg" alt="Checkbox checked">144: Remarks and SignatureRemarksDate of Notice03/07/2024ATTENTION: The person for whose account the securities to which this notice relates are...
="/Images/box-unchecked.jpg" alt="Checkbox not checked">10011/15/2023Cash* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the...
false 0001404644 0001404644 2024-03-04 2024-03-04 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | -0.46 | -11.6455696203 | 3.95 | 4.14 | 3.18 | 23013 | 3.59814973 | CS |
52 | 0.24 | 7.38461538462 | 3.25 | 4.7 | 3.05 | 163060 | 3.71406305 | CS |
156 | -56.11 | -94.144295302 | 59.6 | 67 | 1.875 | 235137 | 13.52525583 | CS |
260 | -16.41 | -82.4623115578 | 19.9 | 90.65 | 1.875 | 272707 | 33.71114395 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions